MCID: TBR001
MIFTS: 65

Tuberous Sclerosis malady

Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Cardiovascular diseases, Nephrological diseases, Skin diseases, Fetal diseases, Cancer diseases categories

Aliases & Classifications for Tuberous Sclerosis

About this section
Sources:
10Disease Ontology, 68Wikipedia, 45NIH Rare Diseases, 46NINDS, 47Novoseek, 12DISEASES, 51Orphanet, 35MedlinePlus, 65UMLS, 36MeSH, 24GTR, 22GeneTests, 59SNOMED-CT, 29ICD9CM, 42NCIt, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 27ICD10
See all sources

Aliases & Descriptions for Tuberous Sclerosis:

Name: Tuberous Sclerosis 10 68 45 46 47 12 51 35 65 36
Tuberous Sclerosis Syndrome 10 24
Tuberous Sclerosis, Type 1 22 24
Tuberous Sclerosis Complex 45 51
Bourneville Syndrome 45 51
Tuberous Sclerosis 1 45 65
Bourneville's Syndrome 45
 
Bourneville's Disease 10
Bourneville Disease 68
Tuberose Sclerosis 10
Cerebral Sclerosis 10
Epiloia 10
Tsc1 22


Classifications:



Characteristics (Orphanet epidemiological data):

51
tuberous sclerosis:
Inheritance: Autosomal dominant; Prevalence: 1-9/1000000 (United States),1-5/10000 (Europe),1-9/100000 (Europe),1-9/100000 (United Kingdom),1-9/100000 (Taiwan, Province of China); Age of onset: Childhood


External Ids:

Disease Ontology10 DOID:13515
ICD9CM29 759.5
MeSH36 D014402
NCIt42 C3424
Orphanet51 805
ICD10 via Orphanet28 Q85.1
MESH via Orphanet37 D014402
UMLS via Orphanet66 C0041341
ICD1027 Q85.1

Summaries for Tuberous Sclerosis

About this section
MedlinePlus:35 Tuberous sclerosis is a rare genetic disease that causes benign tumors to grow in the brain and other organs. symptoms vary, depending on where the tumors grow. they could include skin problems, such as light patches and thickened skin seizures behavior problems intellectual disabilities kidney problems some people have signs of tuberous sclerosis at birth. in others it can take time for the symptoms to develop. the disease can be mild, or it can cause severe disabilities. in rare cases, tumors in vital organs or other symptoms can be life-threatening. tuberous sclerosis has no cure, but treatments can help symptoms. options include medicines, educational and occupational therapy, surgery, or surgery to treat specific complications. nih: national institute of neurological disorders and stroke

MalaCards based summary: Tuberous Sclerosis, also known as tuberous sclerosis syndrome, is related to subependymal giant cell astrocytoma and tuberous sclerosis-1, and has symptoms including prominent occiput, eeg abnormality and neoplasm of the nervous system. An important gene associated with Tuberous Sclerosis is TSC1 (Tuberous Sclerosis 1), and among its related pathways are LKB1 signaling events and Interferon type I. Affiliated tissues include skin, kidney and brain, and related mouse phenotypes are tumorigenesis and muscle.

NIH Rare Diseases:45 Tuberous sclerosis is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body. common signs and symptoms include patches of unusually light-colored skin, areas of raised and thickened skin, and growths under the nails. tumors on the face called facial angiofibromas are also common beginning in childhood. tumors may cause developmental problems (e.g., seizures, hyperactivity, aggression, learning problems, autistic-like behaviors). some tumors can cause serious complications (e.g., those affecting the brain, heart, or kidney). tuberous sclerosis complex has an autosomal dominant pattern of inheritance and can be caused by mutations in the tsc1 or tsc2 gene. last updated: 10/29/2010

NINDS:46 Tuberous sclerosis (TSC) is a rare genetic disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys, heart, eyes, lungs, and skin.

Related Diseases for Tuberous Sclerosis

About this section

Diseases in the Tuberous Sclerosis family:

Tuberous Sclerosis-1

Diseases related to Tuberous Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 488)
idRelated DiseaseScoreTop Affiliating Genes
1subependymal giant cell astrocytoma31.9GFAP, S100B, VIM
2tuberous sclerosis-131.9CCL26, TSC1, TSC2
3lymphangioleiomyomatosis31.8MTOR, RPS6, RPS6KB1, TSC1, TSC2
4kidney cancer31.4MTOR, TSC1, TSC2
5kidney disease31.1AKT1, MTOR, TSC1, TSC2, VIM
6lymphatic neoplasm31.1TSC2, VIM
7chordoma31.1GFAP, S100B, VIM
8grade iii astrocytoma30.8GFAP, NES, S100B, VIM
9clivus chordoma30.7GFAP, S100B, VIM
10kidney benign neoplasm30.6MTOR, TSC1, TSC2
11angiomyoma30.5CCL26, MTOR, TSC1, TSC2
12nervous system disease30.5AKT1, NF1, SYP
13rhabdomyosarcoma30.4GFAP, VIM
14neuromuscular disease30.4GFAP, NF1, S100B
15anaplastic ganglioglioma30.4GFAP, S100B, SYP, VIM
16cerebral arterial disease30.3GFAP, SYP
17peripheral neuropathy30.3AKT1, NF1, SYP
18angiomyolipoma11.0
19astrocytoma11.0
20multiple sclerosis, disease progression, modifier of10.8
21cowden syndrome 110.8
22adrenal cortex disease10.8
23congenital nervous system abnormality10.8
24child syndrome10.7
25kid syndrome10.7
26renal cell carcinoma10.7
27multiple sclerosis 210.7
28cerebritis10.6
29multiple sclerosis 310.6
30aneurysm10.6
31polycystic kidney disease10.6
32giant cell tumor10.6
33multiple sclerosis 510.6
34tsc2 angiomyolipomas, renal, modifier of10.6
35hepatitis10.6
36neurofibromatosis10.6
37kidney angiomyolipoma10.6
38polycystic kidney disease, infantile severe, with tuberous sclerosis10.6
39pancreatitis10.6
40seizure disorder10.6
41perivascular epithelioid cell tumor10.5
42epilepsy syndrome10.5
43nervous system cancer10.5
44retinitis10.5
45vascular cancer10.5
46hemimegalencephaly10.5
47vascular malformation10.5
48skin disease10.5
49brain cancer10.5
50genetic brain disorders10.5

Graphical network of the top 20 diseases related to Tuberous Sclerosis:



Diseases related to tuberous sclerosis

Symptoms for Tuberous Sclerosis

About this section

Symptoms:

 51 (show all 44)
  • prominent occiput/occipital bossing
  • follicular/erythematous/edematous papules/milium
  • cutaneous neurofibromas/facial angiofibromas/koenen tumors
  • adenoma sebaceum
  • pedunculated skin lesions
  • eeg anomalies
  • central nervous system/peripheral nerves neoplasm/tumor/carcinoma/cancer
  • autosomal dominant inheritance
  • retinal hamartoma
  • optic nerve anomaly/optic atrophy/anomaly of the papilla
  • macules
  • irregular/patchy skin hypopigmentation
  • cafe-au-lait spot
  • capillary hemangioma/nevus/naevus flammeus/port-wine stain
  • subcutaneous nodules/lipomas/tumefaction/swelling
  • ungual/paraungual fibromas (fingernails)
  • ungual/parungual fibromas (toenails)
  • seizures/epilepsy/absences/spasms/status epilepticus
  • intellectual deficit/mental/psychomotor retardation/learning disability
  • psychic/behavioural troubles
  • coloboma of iris
  • gingivitis
  • enamel anomaly
  • macrodactyly/fingers hypertrophy/megalodactyly (hand)
  • structural anomalies of the liver and the biliary tract
  • structural anomalies of the pancreas
  • structural anomalies of the respiratory system and diaphragm
  • abnormal pleura/hydrothorax/pleuresia/pleural effusion/chylothorax
  • respiratory distress/dyspnea/respiratory failure/lung volume reduction
  • emphysema
  • visceral angiomatosis (excluding skin)
  • cardiac rhythm disorder/arrhythmia
  • heart/cardiac failure
  • arterial aneurism (excluding aorta)
  • lymphangioma/lymphatic malformations
  • polycystic kidneys
  • renal failure
  • hypothyroidy
  • precocious puberty
  • corpus callosum/septum pellucidum total/partial agenesis
  • intracranial/cerebral calcifications
  • cranial hypertension
  • heart/cardiac tumor
  • kidney/renal neoplasm/tumor/carcinoma/cancer

HPO human phenotypes related to Tuberous Sclerosis:

(show all 36)
id Description Frequency HPO Source Accession
1 prominent occiput hallmark (90%) HP:0000269
2 eeg abnormality hallmark (90%) HP:0002353
3 neoplasm of the nervous system hallmark (90%) HP:0004375
4 adenoma sebaceum hallmark (90%) HP:0009720
5 optic atrophy typical (50%) HP:0000648
6 behavioral abnormality typical (50%) HP:0000708
7 cafe-au-lait spot typical (50%) HP:0000957
8 hypermelanotic macule typical (50%) HP:0001034
9 hypopigmented skin patches typical (50%) HP:0001053
10 seizures typical (50%) HP:0001250
11 retinal hamartoma typical (50%) HP:0009594
12 cognitive impairment typical (50%) HP:0100543
13 ungual fibroma typical (50%) HP:0100804
14 renal insufficiency occasional (7.5%) HP:0000083
15 polycystic kidney dysplasia occasional (7.5%) HP:0000113
16 gingivitis occasional (7.5%) HP:0000230
17 iris coloboma occasional (7.5%) HP:0000612
18 abnormality of dental enamel occasional (7.5%) HP:0000682
19 hypothyroidism occasional (7.5%) HP:0000821
20 precocious puberty occasional (7.5%) HP:0000826
21 abnormality of the liver occasional (7.5%) HP:0001392
22 congestive heart failure occasional (7.5%) HP:0001635
23 abnormality of the pancreas occasional (7.5%) HP:0001732
24 respiratory insufficiency occasional (7.5%) HP:0002093
25 emphysema occasional (7.5%) HP:0002097
26 abnormality of the pleura occasional (7.5%) HP:0002103
27 cerebral calcification occasional (7.5%) HP:0002514
28 increased intracranial pressure occasional (7.5%) HP:0002516
29 aneurysm occasional (7.5%) HP:0002617
30 aplasia/hypoplasia of the corpus callosum occasional (7.5%) HP:0007370
31 renal neoplasm occasional (7.5%) HP:0009726
32 arrhythmia occasional (7.5%) HP:0011675
33 neoplasm of the heart occasional (7.5%) HP:0100544
34 macrodactyly of finger occasional (7.5%) HP:0100746
35 visceral angiomatosis occasional (7.5%) HP:0100761
36 lymphangioma occasional (7.5%) HP:0100764

Drugs & Therapeutics for Tuberous Sclerosis

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Afinitor 15 41 EVEROLIMUS Novartis March 2009
FDA Label: Afinitor
Disease/s that Drug Treats:renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumors/ hormone receptor-positive, HER2-negative breast cancer
Indications and Usage:15 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:13 Serine/threonine-protein kinase mTOR
Mechanism of Action:15 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of thePI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellularprotein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition ofmTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiationfactor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate ofmTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independentactivation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) andreduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shownto reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitrostudies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activityof everolimus in a synergistic manner.Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.

Drugs for Tuberous Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 11742159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
2
Doxycyclineapproved, investigationalPhase 4204564-25-054671203, 5281011
Synonyms:
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10597-92-9
17086-28-1 (mono-hydrate)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)
24390-14-5
41411-66-9 (6-epimer, mono-hydrochloride)
5-Hydroxy-alpha-6-deoxytetracycline
564-25-0
6-Deoxyoxytetracycline
6-Deoxytetracycline
6-alpha-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
69935-17-7 (mono-hydrochloride, di-hydrate)
6alpha-Deoxy-5-oxytetracycline
6α-deoxy-5-oxytetracycline
7164-70-7
7264-10-0
94088-85-4 (calcium salt (1:2))
AB08 (*Fosfatex)
AC1NQXW7
AC1NS4CW
AC1NUYS8
AC1O8PYM
Adoxa
Alodox
Alti-Doxycycline
Apo-Doxy
Atridox
Azudoxat
BCBcMAP01_000024
BIDD:GT0146
BMY-28689
BPBio1_000951
BSPBio_000863
BSPBio_001936
BU-3839T
C06973
CHEBI:50845
CHEMBL1433
CID5281011
CID5353597
CID5463943
CID6713981
CPD001550033
D07876
DB00254
DMSC (*Fosfatex)
DOXCYCLINE ANHYDROUS
DOXY
DOXYCYCLINE CALCIUM
DOXYCYCLINE MONOHYDRATE
Deoxymykoin
DivK1c_000345
Doryx
Dossiciclina
Dossiciclina [DCIT]
Doxcycline anhydrous
Doxiciclina
Doxiciclina [INN-Spanish]
Doxiciclina [Italian]
Doxitard
Doxivetin
Doxy 100
Doxy-Caps
Doxy-Puren
Doxy-Tabs
Doxycen
Doxychel
Doxychel (TN)
Doxycin
Doxycyclin
Doxycycline
Doxycycline (200mg/day) or Placebo
Doxycycline (INN)
 
Doxycycline (TN)
Doxycycline (anhydrous)
Doxycycline (internal use)
Doxycycline Hyclate
Doxycycline Monohydrate
Doxycycline anhydrous
Doxycycline hyclate
Doxycycline hydrochloride
Doxycycline-Chinoin
Doxycyclinum
Doxycyclinum [INN-Latin]
Doxysol
Doxytec
Doxytetracycline
EINECS 209-271-1
GS-3065 (*monohydrate)
HMS2090E06
HSDB 3071
Hydramycin
IDI1_000345
Investin
Jenacyclin
KBio1_000345
KBio2_001287
KBio2_003855
KBio2_006423
KBio3_001156
KBioGR_001133
KBioSS_001287
LS-187766
LS-93868
Liviatin
Lopac0_000405
MolPort-002-507-423
Monodox
Monodox (*monohydrate)
Morgidox
NCGC00161602-01
NCGC00161602-03
NCGC00161602-04
NCGC00167961-01
NCGC00179395-01
NINDS_000345
NSC633557
Novo-Doxylin
Nu-Doxycycline
Ocudox
Oracea
Prestwick0_000852
Prestwick1_000852
Prestwick2_000852
Prestwick3_000852
Ronaxan
SAM002589932
SMP1_000107
SPBio_000246
SPBio_002784
STOCK1N-34341
Spanor
Spectrum2_000143
Spectrum3_000408
Spectrum4_000527
Spectrum5_000947
Spectrum_000807
Supracyclin
UNII-334895S862
UPCMLD-DP021
UPCMLD-DP021:001
Vibra-tabs
Vibramycin
Vibramycin (*monohydrate)
Vibramycin Monohydrate
Vibramycin Novum
Vibramycine
Vibravenos
Vivox (*Hyclate)
alpha-6-Deoxy-5-hydroxytetracycline
alpha-6-Deoxyoxytetracycline
alpha-Doxycycline
doxycycline
3
Miconazoleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1291222916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
4
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1174253123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
5
VigabatrinapprovedPhase 41960643-86-95665
Synonyms:
( inverted question mark)-gamma-Vinyl GABA
(?)-gamma-Vinyl GABA
(R,S)-4-Amino-5-hexenoic acid
.gamma.-Vinyl-.gamma.-aminobutyric acid
.gamma.-Vinyl-GABA
4-Amino-5-hexenoic acid
4-Aminohexenoic acid
4-aminohex-5-enoic acid
60643-86-9
74046-07-4
AB00053309
AC1L1KUZ
Acid, gamma-Vinyl-gamma-Aminobutyric
Aventis Brand of Vigabatrin
BPBio1_000465
BPBio1_000925
BSPBio_000421
BSPBio_003469
Biomol-NT_000247
C07500
C6H11NO2
CHEBI:241484
CHEMBL89598
CID5665
CPP-109
D00535
D020888
DB01080
DivK1c_006760
EU-0101277
GVG
HMS1569F03
HMS2094M21
Hexenoic acid, 4-amino
Hoechst Brand of Vigabatrin
KBio1_001704
KBio2_000848
KBio2_003416
KBio2_005984
KBio3_002973
KBioSS_000848
LS-75569
Lopac0_001277
M071754
MDL 71,754
MDL 71754
 
MDL-71754
MolPort-003-666-796
NCGC00016087-03
NCGC00016087-08
NCGC00024802-02
NCGC00024802-03
NCGC00024802-04
NCGC00024802-05
NCGC00024802-06
Prestwick0_000501
Prestwick1_000501
Prestwick2_000501
Prestwick3_000501
Prestwick_837
RMI 71754
RMI-71754
RMI-71890
SPBio_002342
SPECTRUM1502036
Sabril
Sabril (TN)
Sabrilex
SpecPlus_000664
Spectrum3_001825
Spectrum_000368
V 8261
V8261_SIGMA
Vigabatrin
Vigabatrin (JAN/USAN/INN)
Vigabatrin Aventis Brand
Vigabatrin Hoechst Brand
Vigabatrin Yamanouchi Brand
Vigabatrin [USAN:BAN:INN]
Vigabatrin [USAN:INN:BAN]
Vigabatrina
Vigabatrina [Spanish]
Vigabatrine
Vigabatrine [French]
Vigabatrinum
Vigabatrinum [Latin]
Yamanouchi Brand of Vigabatrin
gamma Vinyl GABA
gamma Vinyl gamma Aminobutyric Acid
gamma-Vinyl GABA
gamma-Vinyl-GABA
gamma-Vinyl-gamma-Aminobutyric Acid
gamma-Vinyl-gamma-aminobutyric acid
vigabatrin
6
PrednisoloneapprovedPhase 3103350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
Flo-pred
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
MLS001304083
 
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
Millipred
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Omnipred
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
7
MethylprednisoloneapprovedPhase 3103383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
A-methapred
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Depo-medrol
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Solu-medrol
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
8
Melatoninapproved, nutraceuticalPhase 3, Phase 121573-31-4896
Synonyms:
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-Methoxy-N-acetyltryptamine
5-methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
AKOS000276269
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
BAS 01281092
BIDD:ER0618
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
Bio-0635
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
CID896
ChemDiv2_003916
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
LS-1623
Lopac-M-5250
Lopac0_000787
M 5250
M-1200
M-1250
M1105
M5250_SIGMA
ML1
MLS000859594
MLS001055382
MLS001240204
MT6
Mela-T
Melapure
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
 
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
Melovine
MolPort-000-737-883
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-Acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine Melatonine
N-Acetyl-5-methoxytryptamine
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-acetyl-5-methoxy-tryptamine
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Nature'S Harmony
Night Rest
Oprea1_104553
Oprea1_814234
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Pineal Hormone
Posidorm
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
Prestwick_312
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
SPECTRUM1500690
STK386880
Sleep Right
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
Spectrum_000185
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} Acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} Acetamide
9Prednisolone acetatePhase 31033
10Prednisolone hemisuccinatePhase 31033
11Prednisolone phosphatePhase 31033
12Methylprednisolone acetatePhase 31033
13Methylprednisolone HemisuccinatePhase 31033
14Phase 3
15StrawberryNutraceuticalPhase 371
16
MetforminapprovedPhase 21573657-24-9, 1115-70-414219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMBG
DMGG
Diabefagos
Diabetosan
Diabex
Diaformin
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Meguan
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin Hydrochloride
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
Obimet
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
17
Octreotideapproved, investigationalPhase 219183150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
 
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Ocphyl
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatin
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
18
Letrozoleapproved, investigationalPhase 2326112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
19
SimvastatinapprovedPhase 1, Phase 248279902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
20
Propranololapproved, investigationalPhase 2194525-66-64946
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
13013-17-7
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
AY 64043
AY-20694
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
BPBio1_001040
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
Bedranol
Beprane
Berkolol
Beta Neg
Beta-Neg
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Betachron
Betadren
Betalong
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
C07407
C16H21NO2
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
Cardinol
Caridolol
Corpendol
D,L-Propranolol
D08443
DB00571
DL-Propranolol hydrochloride
Deralin
DivK1c_000023
Dl-Propranolol Hydrochloride
Dociton
Duranol
EINECS 208-378-0
EINECS 235-867-6
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HMS2090L21
Hemangeol
Herzbase
ICI 45520
IDI1_000023
INDERIDE-40/25
INDERIDE-80/25
Ikopal
Inderal
Inderal LA
Inderal La
Inderal hydrochloride
Inderalici
Inderex
Inderide
Inderol
Indobloc
 
Innopran XL
Innopran Xl
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
LS-122410
LS-184129
Lopac0_000896
Migrastat
MolPort-001-794-623
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Naprilin
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Prano-Puren
Pranolol
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol Hydrochloride
Propranolol [INN:BAN]
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor Line
Reducor line
SPBio_001361
SPBio_001658
SPBio_003093
STK735510
Sagittol
Sawatal
Servanolol
Sloprolol
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
Sumial
Tesnol
UNII-9Y8NXQ24VQ
b-Propranolol
beta-Propranolol
cMAP_000071
etalong
propranolol
propranololo
β-Propranolol
21FluoridesPhase 1327
22
Progesteroneapproved47357-83-05994
Synonyms:
(S)-4-Pregnene-3,20-dione
(S)-Pregn-4-en-3,20-dione
(S)-Progesterone
.beta.-Progesterone
.delta.(sup4)-Pregnene-3,20-dione
.delta.4-Pregnene-3,20-dione
17.alpha.-Progesterone
17a-Progesterone
17alpha-Progesterone
17alpha-progesterone
17α-progesterone
1dbb
1h60
257630-50-5
3,20-Pregnene-4
32104FB6-BF81-4F6E-83C2-024DEEAEB272
4-Pregnen-3,20-dione
4-Pregnene-3,20-dione
46665_FLUKA
46665_RIEDEL
57-83-0
753497-20-0
8012-32-6
8023-13-0
AC-700
AC1L1LKF
AI3-51682
Agolutin
Akrolutin
BB_NC-0185
BHR-100
BIDD:ER0547
BIDD:PXR0094
BPBio1_000676
BRD-K64994968-001-03-6
BSPBio_000614
Bio-luton
C00410
CCRIS 533
CHEBI:17026
CHEMBL103
CID5994
CIDR
CMC_13406
COL-1620
CPD000058345
Colprosterone
Corlutin
Corlutina
Corluvite
Corporin
Corpus Luteum Hormone
Corpus luteum hormone
Crinone
Crinone (TN)
Crinone progesterone gel
Curretab
Cyclogest
Cyclogesterin
D00066
D4-Pregnene-3,20-dione
DB00396
DR-2011
Delalutin
Delta(4)-pregnene-3,20-dione
Duraprogen
EINECS 200-350-6
ETI-411
EU-0100895
Endometrin
Estima
FE-999913
Flavolutan
Fologenon
Gelbkoerperhormon
Gesterol
Gesterol 100
Gesterol 50
Gestiron
Gestone
Gestormone
Gestron
Glanducorpin
Gynlutin
Gynoluton
Gynolutone
HMS1569O16
HMS2051O05
HMS2090J07
HSDB 3389
Hormoflaveine
Hormoluton
Hydroxyprogesterone Caproate
Hydroxyprogesterone Caproic acid
LMST02030159
LS-234
Lingusorbs
Lipo-Lutin
Lipolutin
Lopac0_000895
Lucorteum
Lucorteum Sol
Lucorteum sol
Lugesteron
Luteal hormone
Luteinique
Luteocrin normale
Luteodyn
Luteogan
Luteohormone
Luteol
Luteol (VAN)
Luteopur
Luteosan
Luteostab
Luteovis
Luteum
Lutex
Lutidon
Lutin
Lutinus
Lutociclina
Lutocuclin M
Lutocyclin
Lutocyclin M
 
Lutocyclin m
Lutocylin
Lutocylol
Lutoform
Lutogyl
Lutogynon
Lutren
Lutromone
MLS000028517
MLS000758277
MLS001074187
MLS002222367
MPA
Membrettes
Methylpregnone
Micronized Progesterone
MolPort-001-794-643
NCGC00022185-03
NCGC00022185-04
NCGC00022185-05
NCGC00022185-06
NCGC00022185-07
NCGC00022185-08
NCGC00022185-09
NCGC00090798-01
NCGC00090798-02
NCI60_042166
NSC 64377
NSC 9704
NSC-9704
NSC64377
NSC9704
Nalutron
Natural Progesterone
P 0130
P0130_SIGMA
P0478
P3972_SIGMA
P6149_SIGMA
P7556_ALDRICH
P7556_SIGMA
P8783_SIGMA
P9776_SIGMA
PROGESTERONE
Percutacrine
Percutacrine Luteinique
Piaponon
Pranone
Pregn-4-en-3,20-dione
Pregn-4-ene-3,20-dione
Pregnene-3,20-dione
Pregnenedione
Prestwick0_000477
Prestwick1_000477
Prestwick2_000477
Prestwick3_000477
Prestwick_411
Primolut
Prochieve
Progeffik
Progekan
Progestan
Progestasert
Progesterol
Progesteron
Progesterona
Progesterona [INN-Spanish]
Progesterone
Progesterone (JP15/USP/INN)
Progesterone [INN:BAN:JAN]
Progesterone [Progestins]
Progesterone, water-soluble
Progesterone-Water Soluble
Progesterone: HBC complex
Progesteronum
Progesteronum [INN-Latin]
Progestin
Progestogel
Progestol
Progeston
Progestone
Progestosol
Progestrel
Progestron
Progestronol
Progestérone
Projestaject
Prolets
Prolidon
Prolutin
Proluton
Prolutone
Prometrium
Prometrium (TN)
Prontogest
Protormone
S00293
S1705_Selleck
SAM001247039
SMR000058345
SMR000653542
SPBio_002553
SR-01000000088
SR-01000000088-5
Spectrum5_002053
Syngesterone
Syngestrets
Synovex S
Syntolutan
U 3672
UNII-4G7DS2Q64Y
Utrogest
Utrogestan
Vitarrine
WLN: L E5 B666 OV MUTJ A1 E1 FV1
ZINC04428529
beta-Progesterone
bmse000482
component of Cyclogesterin
corpus luteum hormone
delta(4)-Pregnene-3,20-dione
delta(Sup 4)-Pregnene-3,20-dione
delta(Sup4)-pregnene-3,20-dione
delta(sup 4)-Pregnene-3,20-dione
delta4-Pregnene-3,20-dione
luteohormone
nchembio.2007.53-comp14
23
Nitric Oxideapproved54010102-43-9145068
Synonyms:
(.)NO
(NO)(.)
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous Nitrate Vasodilator
Endothelium-Derived Nitric Oxide
HNO
HSDB 1246
INOmax
INOmax (TN)
Inomax
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, Mononitrogen
Monoxide, Nitrogen
Monoxido de nitrogeno
Monoxyde d'azote
NITRIC-OXIDE
NO
NO(.)
Nitrate Vasodilator, Endogenous
Nitric Oxide, Endothelium Derived
 
Nitric Oxide, Endothelium-Derived
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
OHM 11771
Oxide, Nitric
Oxido de nitrogeno(ii)
Oxido nitrico
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoff(ii)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, Endogenous Nitrate
[NO]
endothelium-derived relaxing factor
monoxido de nitrogeno
monoxyde d'azote
nitric oxide
nitrogen monooxide
nitrogen monoxide
nitrosyl
oxido de nitrogeno(II)
oxido nitrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
24Protein C Inhibitor81
25Alpha 1-Antitrypsin83

Interventional clinical trials:

(show top 50)    (show all 52)
idNameStatusNCT IDPhase
1Rapamycin In Angiomyolipomas In Patients With Tuberous SclerosisCompletedNCT01217125Phase 4
2Doxycycline In Lymphangioleiomyomatosis (LAM)CompletedNCT00989742Phase 4
3Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) PatientsRecruitingNCT01266291Phase 4
4Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301Active, not recruitingNCT02338609Phase 4
5Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)CompletedNCT00789828Phase 3
6Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00790400Phase 3
7Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis ComplexRecruitingNCT01730209Phase 2, Phase 3
8Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment DisabilitiesRecruitingNCT01906866Phase 3
9A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresActive, not recruitingNCT01713946Phase 3
10Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous MethylprednisoloneActive, not recruitingNCT00004645Phase 3
11Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis ComplexNot yet recruitingNCT02634931Phase 3
12Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)Not yet recruitingNCT02635789Phase 3
13A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Focal Seizures in Tuberous Sclerosis Complex.Not yet recruitingNCT02544763Phase 3
14An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Focal Seizures in Tuberous Sclerosis Complex.Not yet recruitingNCT02544750Phase 3
15Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAMCompletedNCT00457808Phase 2
16Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)CompletedNCT01289912Phase 2
17Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis ComplexCompletedNCT00411619Phase 1, Phase 2
18Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00792766Phase 1, Phase 2
19RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAMCompletedNCT00457964Phase 1, Phase 2
20Topical Rapamycin to Erase Angiofibromas in TSCCompletedNCT01526356Phase 2
21A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous SclerosisRecruitingNCT01954693Phase 2
22Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockersRecruitingNCT02104011Phase 2
23A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCDRecruitingNCT02451696Phase 2
24Safety of Simvastatin in LAM and TSCRecruitingNCT02061397Phase 1, Phase 2
25Everolimus for Cancer With TSC1 or TSC2 MutationRecruitingNCT02201212Phase 2
26Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial CancerRecruitingNCT02188550Phase 2
27Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETsRecruitingNCT02294006Phase 2
28Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)Active, not recruitingNCT01070316Phase 1, Phase 2
29Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAMActive, not recruitingNCT00490789Phase 2
30Rapalogues for Autism Phenotype in TSC: A Feasibility StudyActive, not recruitingNCT01929642Phase 2
31Sirolimus in Treating Patients With Angiomyolipoma of the KidneyActive, not recruitingNCT00126672Phase 2
32A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComaWithdrawnNCT01690871Phase 2
33Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)CompletedNCT01031901Phase 1
34Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep DisturbancesCompletedNCT01903681Phase 1
35Tuberous Sclerosis Complex: Facial Angiofibroma Skin CreamRecruitingNCT01853423Phase 1
36Effect of Fasting on the Size of Abdominal Lymphatic Tumors in WomenCompletedNCT00552955
37Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)CompletedNCT00001869
38Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)RecruitingNCT01780441
39Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis ComplexRecruitingNCT02654340
40Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)RecruitingNCT02461459
41Study of Skin Tumors in Tuberous SclerosisRecruitingNCT00001975
42Tuberous Sclerosis Complex Natural History Study: Renal ManifestationsRecruitingNCT00598455
43The Cognitive Variability in NF1 and TSC Monozygotic TwinsRecruitingNCT02436746
44Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis ComplexRecruitingNCT02098759
45Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis ComplexRecruitingNCT02687633
46Study of the Disease Process of LymphangioleiomyomatosisRecruitingNCT00001465
47Role of Genetic Factors in the Development of Lung DiseaseRecruitingNCT00001532
48Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric TumorsRecruitingNCT02334930
49Genetic Studies in Patients and Families With Infantile SpasmsRecruitingNCT01723787
50Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSCActive, not recruitingNCT01767779

Search NIH Clinical Center for Tuberous Sclerosis


Cochrane evidence based reviews: Tuberous Sclerosis

Genetic Tests for Tuberous Sclerosis

About this section

Genetic tests related to Tuberous Sclerosis:

id Genetic test Affiliating Genes
1 Tuberous Sclerosis 122 24 TSC1
2 Tuberous Sclerosis Syndrome24

Anatomical Context for Tuberous Sclerosis

About this section

MalaCards organs/tissues related to Tuberous Sclerosis:

33
Skin, Kidney, Brain, Heart, Lung, Eye, Breast

Animal Models for Tuberous Sclerosis or affiliated genes

About this section

MGI Mouse Phenotypes related to Tuberous Sclerosis:

38 (show all 17)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.3AKT1, AKT3, NF1, PKD1, RPS6KB1, TSC1
2MP:00053698.9AKT1, GFAP, MTOR, NF1, PKD1, RHEB
3MP:00053808.7AKT1, MTOR, NES, NF1, PKD1, RHEB
4MP:00028738.5AKT1, AKT3, DBH, GFAP, MTOR, NF1
5MP:00053878.1AKT1, AKT3, GFAP, MTOR, NF1, PKD1
6MP:00053858.0AKT1, DBH, EIF4EBP1, GFAP, NF1, PKD1
7MP:00053868.0AKT1, AKT3, DBH, DCX, GFAP, MTOR
8MP:00053797.9AKT1, AKT3, DBH, NF1, PKD1, RPS6
9MP:00036317.6AKT1, AKT3, DBH, DCX, GFAP, MTOR
10MP:00053787.4AKT1, AKT3, DBH, DCX, EIF4EBP1, GFAP
11MP:00053847.1AKT1, AKT3, EIF4EBP1, GFAP, MTOR, NES
12MP:00053767.1AKT1, AKT3, DBH, EIF4EBP1, GFAP, MTOR
13MP:00107687.1AKT1, AKT3, DBH, DCX, EIF4EBP1, GFAP

Publications for Tuberous Sclerosis

About this section

Articles related to Tuberous Sclerosis:

(show top 50)    (show all 1283)
idTitleAuthorsYear
1
Age-related changes of susceptibility-weighted imaging in subependymal nodules of neonates and children with tuberous sclerosis complex. (25907013)
2015
2
Topographical Distribution of Epileptogenic Tubers in Patients With Tuberous Sclerosis Complex. (26472749)
2015
3
Multiple ungual fibromas as an only cutaneous manifestation of tuberous sclerosis complex. (25201855)
2014
4
Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options. (25364257)
2014
5
Recovery of chylous pulmonary congestion in tuberous sclerosis complex-associated lymphangioleiomyomatosis. (25326562)
2014
6
Fetal and Postnatal Magnetic Resonance Imaging of Unilateral Cystic Renal Dysplasia in a Neonate with Tuberous Sclerosis. (24495558)
2014
7
Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation. (22805177)
2013
8
Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. (24271014)
2013
9
Giant pilomatricoma in a patient with tuberous sclerosis, both diagnosed in the adult life. (23988820)
2013
10
The ability of high field strength 7-T magnetic resonance imaging to reveal previously uncharacterized brain lesions in patients with tuberous sclerosis complex. (23289918)
2013
11
Polycystic kidney disease and chronic renal failure in tuberous sclerosis. (24092520)
2013
12
Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures. (22752486)
2013
13
T2 weighted MRI for assessing renal lesions in transgenic mouse models of tuberous sclerosis. (21802234)
2012
14
Enhanced GABAergic network and receptor function in pediatric cortical dysplasia Type IIB compared with Tuberous Sclerosis Complex. (21889982)
2012
15
Clinical features distinguish childhood chordoma associated with tuberous sclerosis complex (TSC) from chordoma in the general paediatric population. (21266383)
2011
16
Facial unilateral angiofibromas: a postzygotic tuberous sclerosis like mutation. (22016299)
2011
17
Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis. (21629335)
2011
18
Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. (21692602)
2011
19
Neuropsychological attention skills and related behaviours in adults with tuberous sclerosis complex. (21191642)
2011
20
The morphologic spectrum of uterine PEC-cell associated tumors in a patient with tuberous sclerosis. (21293289)
2011
21
Genetic analysis of tuberous-sclerosis genes 1 and 2 in nonlesional focal epilepsy. (21555252)
2011
22
Intractable epilepsy in tuberous sclerosis: is the tuber removal not enough? (21175458)
2010
23
Prenatal diagnosis of rhabdomyomas and cerebral tuberous sclerosis by magnetic resonance imaging in one fetus of a dizygotic twin pregnancy associated with a frameshift mutation in the TSC2 gene. (21056333)
2010
24
The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. (18845692)
2009
25
Epilepsy surgery and tuberous sclerosis complex: special considerations. (18759614)
2008
26
Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. (18350576)
2008
27
Metastatic breast carcinoma to renal angiomyolipomas in tuberous sclerosis. (18308125)
2008
28
Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. (17727667)
2008
29
The correlation between 1H-MR spectroscopy and clinical manifestation with tuberous sclerosis complex. (17985261)
2007
30
The Birt-Hogg-Dube and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in Schizosaccharomyces pombe. (17556368)
2007
31
Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. (17942919)
2007
32
A defect in protein farnesylation suppresses a loss of Schizosaccharomyces pombe tsc2+, a homolog of the human gene predisposing to tuberous sclerosis complex. (16624901)
2006
33
Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. (16914728)
2006
34
Effect of melatonin dosage on sleep disorder in tuberous sclerosis complex. (15791928)
2005
35
Conservative management of pulmonary lymphangioleiomyomatosis and tuberous sclerosis complicated by renal angiomyolipomas in pregnancy. (15209123)
2004
36
Tuberous sclerosis with hypothyroidism and precocious puberty. (15080418)
2004
37
Tuberous sclerosis: immunohistochemistry expression of tuberin and hamartin in a 31-week gestational fetus. (16095035)
2004
38
14-3-3beta binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin. (12468542)
2003
39
Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. (12842888)
2003
40
Novel TSC1 and TSC2 mutations in Japanese patients with tuberous sclerosis complex. (12015165)
2002
41
Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. (12167664)
2002
42
Ophthalmic manifestations of tuberous sclerosis: a population based study. (11264130)
2001
43
Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. (9568761)
1998
44
Multifocal alveolar hyperplasia associated with lymphangioleiomyomatosis in tuberous sclerosis. (9205862)
1997
45
Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesions of patients with tuberous sclerosis. (8944308)
1996
46
Tissue and cell-type specific expression of the tuberous sclerosis gene, TSC2, in human tissues. (8933518)
1996
47
An autopsy case of tuberous sclerosis. Histological and immunohistochemical study. (1457992)
1992
48
Factor XIIIa in the hamartomas of tuberous sclerosis. (1675869)
1991
49
Hepatic angiomyolipoma in a tuberous sclerosis patient. (2401620)
1990
50
Subependymal giant-cell astrocytoma associated with tuberous sclerosis. Do subependymal nodules grow? (2702677)
1989

Variations for Tuberous Sclerosis

About this section

Clinvar genetic disease variations for Tuberous Sclerosis:

5 (show all 114)
id Gene Variation Type Significance SNP ID Assembly Location
1TSC2TSC2, 1-BP DEL, 5110AdeletionPathogenic
2TSC2NM_000548.3(TSC2): c.4642delC (p.Leu1548Cysfs)deletionPathogenicrs137854083GRCh37Chr 16, 2135303: 2135303
3TSC2NM_000548.3(TSC2): c.5024C> T (p.Pro1675Leu)single nucleotide variantPathogenicrs45483392GRCh37Chr 16, 2137898: 2137898
4TSC2NM_000548.3(TSC2): c.34A> T (p.Lys12Ter)single nucleotide variantPathogenicrs45512692GRCh37Chr 16, 2098650: 2098650
5TSC2NM_000548.3(TSC2): c.2056_2059dupTACT (p.Ser687Leufs)duplicationPathogenicrs137854337GRCh37Chr 16, 2121894: 2121897
6TSC2NM_000548.3(TSC2): c.1513C> T (p.Arg505Ter)single nucleotide variantPathogenicrs45517179GRCh37Chr 16, 2114342: 2114342
7TSC2NM_000548.3(TSC2): c.1832G> A (p.Arg611Gln)single nucleotide variantPathogenicrs28934872GRCh37Chr 16, 2120572: 2120572
8TSC2NM_000548.3(TSC2): c.2150T> G (p.Leu717Arg)single nucleotide variantPathogenicrs45517214GRCh37Chr 16, 2122294: 2122294
9TSC2NM_000548.3(TSC2): c.1432C> T (p.Gln478Ter)single nucleotide variantPathogenicrs121964862GRCh37Chr 16, 2113043: 2113043
10TSC2NM_000548.3(TSC2): c.4508A> C (p.Gln1503Pro)single nucleotide variantPathogenicrs45516293GRCh37Chr 16, 2134966: 2134966
11TSC2NM_000548.3(TSC2): c.5238_5255del18 (p.His1746_Arg1751del)deletionPathogenicrs137854218GRCh37Chr 16, 2138305: 2138322
12TSC2NM_000548.3(TSC2): c.2714G> A (p.Arg905Gln)single nucleotide variantPathogenicrs45517259GRCh37Chr 16, 2126143: 2126143
13TSC2NM_000548.3(TSC2): c.2713C> T (p.Arg905Trp)single nucleotide variantPathogenicrs45517258GRCh37Chr 16, 2126142: 2126142
14TSC2NM_000548.3(TSC2): c.2713C> G (p.Arg905Gly)single nucleotide variantPathogenicrs45517258GRCh37Chr 16, 2126142: 2126142
15TSC2NM_000548.3(TSC2): c.2355+2_2355+5delTAGGdeletionPathogenicrs137854250GRCh37Chr 16, 2122986: 2122989
16TSC2NM_000548.3(TSC2): c.1322G> A (p.Trp441Ter)single nucleotide variantPathogenicrs45515894GRCh37Chr 16, 2112562: 2112562
17TSC1NM_000368.4(TSC1): c.2515_2518delGAGT (p.Glu839Argfs)deletionPathogenicrs794727320GRCh37Chr 9, 135776209: 135776212
18TSC2NM_000548.3(TSC2): c.4415delG (p.Gly1472Alafs)deletionPathogenicrs794727573GRCh37Chr 16, 2134638: 2134638
19TSC2NM_000548.3(TSC2): c.649-1G> Csingle nucleotide variantPathogenicrs794727906GRCh37Chr 16, 2106644: 2106644
20TSC2NP_000539.2: p.Gln1579Proprotein onlyPathogenic
21TSC1NM_000368.4(TSC1): c.2675_2676delGA (p.Arg892Lysfs)deletionPathogenicGRCh38Chr 9, 132897560: 132897561
22TSC2NM_000548.3(TSC2): c.45dupT (p.Lys16Terfs)duplicationPathogenicGRCh37Chr 16, 2098661: 2098661
23TSC1NM_000368.4(TSC1): c.1152delA (p.Gly385Glufs)deletionPathogenicrs118203501GRCh37Chr 9, 135786069: 135786069
24TSC1NM_000368.4(TSC1): c.1257delC (p.Arg420Glyfs)deletionPathogenicrs118203506GRCh37Chr 9, 135785964: 135785964
25TSC1NM_000368.4(TSC1): c.1431_1434delAGAA (p.Glu478Lysfs)deletionPathogenicrs118203527GRCh37Chr 9, 135782122: 135782125
26TSC1NM_000368.4(TSC1): c.1525C> T (p.Arg509Ter)single nucleotide variantPathogenicrs118203542GRCh37Chr 9, 135781440: 135781440
27TSC1NM_000368.4(TSC1): c.1580_1581delAG (p.Gln527Argfs)deletionPathogenicrs118203550GRCh37Chr 9, 135781384: 135781385
28TSC1NM_000368.4(TSC1): c.1959dupA (p.Gln654Thrfs)duplicationPathogenicrs118203603GRCh37Chr 9, 135781006: 135781006
29TSC1NM_000368.4(TSC1): c.1963C> T (p.Gln655Ter)single nucleotide variantPathogenicrs118203606GRCh37Chr 9, 135781002: 135781002
30TSC1NM_000368.4(TSC1): c.1997+1G> Asingle nucleotide variantPathogenicrs118203610GRCh37Chr 9, 135780967: 135780967
31TSC1NM_000368.4(TSC1): c.2074C> T (p.Arg692Ter)single nucleotide variantPathogenicrs118203631GRCh37Chr 9, 135779172: 135779172
32TSC1NM_000368.4(TSC1): c.211-2A> Csingle nucleotide variantPathogenicrs118203352GRCh37Chr 9, 135801128: 135801128
33TSC1NM_000368.4(TSC1): c.2356C> T (p.Arg786Ter)single nucleotide variantPathogenicrs118203682GRCh37Chr 9, 135778027: 135778027
34TSC1NM_000368.4(TSC1): c.2509_2512delAACA (p.Asn837Valfs)deletionPathogenicrs118203708GRCh37Chr 9, 135776215: 135776218
35TSC1NM_000368.4(TSC1): c.2569delG (p.Glu857Argfs)deletionPathogenicrs118203712GRCh37Chr 9, 135776158: 135776158
36TSC1NM_000368.4(TSC1): c.271_272delTC (p.Ser91Valfs)deletionPathogenicrs118203360GRCh37Chr 9, 135801065: 135801066
37TSC1NM_000368.4(TSC1): c.491G> A (p.Trp164Ter)single nucleotide variantPathogenicrs118203387GRCh37Chr 9, 135798752: 135798752
38TSC1NM_000368.4(TSC1): c.664-1G> Csingle nucleotide variantPathogenicrs118203423GRCh37Chr 9, 135796824: 135796824
39TSC1NM_000368.4(TSC1): c.682C> T (p.Arg228Ter)single nucleotide variantPathogenicrs118203427GRCh37Chr 9, 135796805: 135796805
40TSC1NM_000368.4(TSC1): c.733C> T (p.Arg245Ter)single nucleotide variantPathogenicrs118203434GRCh37Chr 9, 135796754: 135796754
41TSC1NM_000368.4(TSC1): c.737+1G> Asingle nucleotide variantPathogenicrs118203438GRCh37Chr 9, 135796749: 135796749
42TSC1NM_000368.4(TSC1): c.812_813delAT (p.Tyr271Terfs)deletionPathogenicrs118203451GRCh37Chr 9, 135787769: 135787770
43TSC1NM_000368.4(TSC1): c.901_902delCA (p.Gln301Glufs)deletionPathogenicrs118203464GRCh37Chr 9, 135787680: 135787681
44TSC1NM_000368.4(TSC1): c.973C> T (p.Gln325Ter)single nucleotide variantPathogenicrs118203474GRCh37Chr 9, 135786896: 135786896
45TSC1NM_000368.4(TSC1): c.989_990delTG (p.Leu330Glnfs)deletionPathogenicrs118203479GRCh37Chr 9, 135786879: 135786880
46TSC1NM_000368.4(TSC1): c.989dupT (p.Ser331Glufs)duplicationPathogenicrs118203478GRCh37Chr 9, 135786880: 135786880
47TSC2NM_000548.3(TSC2): c.1372C> T (p.Arg458Ter)single nucleotide variantPathogenicrs45517169GRCh37Chr 16, 2112983: 2112983
48TSC2NM_000548.3(TSC2): c.226-2A> Gsingle nucleotide variantPathogenicrs45517096GRCh37Chr 16, 2103341: 2103341
49TSC2NM_000548.3(TSC2): c.2356-2A> Csingle nucleotide variantPathogenicrs45517229GRCh37Chr 16, 2124199: 2124199
50TSC2NM_000548.3(TSC2): c.3095G> C (p.Arg1032Pro)single nucleotide variantLikely pathogenicrs45491698GRCh37Chr 16, 2129161: 2129161
51TSC2NM_000548.3(TSC2): c.3206_3207delTG (p.Val1069Aspfs)deletionPathogenicrs137854076GRCh37Chr 16, 2129351: 2129352
52TSC2NM_000548.3(TSC2): c.3412C> T (p.Arg1138Ter)single nucleotide variantPathogenicrs45451497GRCh37Chr 16, 2130180: 2130180
53TSC2NM_000548.3(TSC2): c.352dupG (p.Val118Glyfs)duplicationPathogenicrs137853982GRCh37Chr 16, 2104312: 2104312
54TSC2NM_000548.3(TSC2): c.4115_4116delTG (p.Val1372Glyfs)deletionPathogenicrs137854368GRCh37Chr 16, 2134338: 2134339
55TSC2NM_000548.3(TSC2): c.4544_4547delACAA (p.Asn1515Serfs)deletionPathogenicrs137854175GRCh37Chr 16, 2135002: 2135005
56TSC2NM_000548.3(TSC2): c.4573C> T (p.Gln1525Ter)single nucleotide variantPathogenicrs45517352GRCh37Chr 16, 2135234: 2135234
57TSC2NM_000548.3(TSC2): c.4842_4844delCAT (p.Ile1614del)deletionPathogenicrs137854331GRCh37Chr 16, 2136373: 2136375
58TSC2NM_000548.3(TSC2): c.5150T> C (p.Leu1717Pro)single nucleotide variantPathogenicrs45517398GRCh37Chr 16, 2138130: 2138130
59TSC2NM_000548.3(TSC2): c.5252_5259+19del27deletionPathogenicrs137854397GRCh37Chr 16, 2138319: 2138345
60TSC2NM_000548.3(TSC2): c.646G> T (p.Glu216Ter)single nucleotide variantPathogenicrs45517118GRCh37Chr 16, 2106243: 2106243
61TSC2NM_000548.3(TSC2): c.976-15G> Asingle nucleotide variantPathogenicrs45517150GRCh37Chr 16, 2110656: 2110656
62TSC2NM_000548.3(TSC2): c.648+1G> Asingle nucleotide variantPathogenicrs45488893GRCh37Chr 16, 2106246: 2106246
63TSC2NM_000548.3(TSC2): c.5259+1delGdeletionPathogenicrs137854317GRCh37Chr 16, 2138327: 2138327
64TSC2NM_000548.3(TSC2): c.5160+1G> Asingle nucleotide variantPathogenicrs45517399GRCh37Chr 16, 2138141: 2138141
65TSC2NM_000548.3(TSC2): c.826_827delAT (p.Met276Valfs)deletionPathogenicrs137853977GRCh37Chr 16, 2107157: 2107158
66TSC2NM_000548.3(TSC2): c.4989+1G> Asingle nucleotide variantPathogenicrs45517386GRCh37Chr 16, 2136873: 2136873
67TSC2NM_000548.3(TSC2): c.5227C> T (p.Arg1743Trp)single nucleotide variantPathogenicrs45517412GRCh37Chr 16, 2138294: 2138294
68TSC2NM_000548.3(TSC2): c.4318C> T (p.Gln1440Ter)single nucleotide variantPathogenicrs45517337GRCh37Chr 16, 2134541: 2134541
69TSC2NM_000548.3(TSC2): c.3696dupT (p.Asn1233Terfs)duplicationPathogenicrs137854210GRCh37Chr 16, 2131681: 2131681
70TSC2NM_000548.3(TSC2): c.4096G> T (p.Glu1366Ter)single nucleotide variantPathogenicrs45517327GRCh37Chr 16, 2134319: 2134319
71TSC2NM_000548.3(TSC2): c.2666C> T (p.Ala889Val)single nucleotide variantPathogenicrs137854155GRCh37Chr 16, 2126095: 2126095
72TSC2NM_000548.3(TSC2): c.2459_2461delTCA (p.Ile820del)deletionLikely pathogenicrs137854128GRCh37Chr 16, 2124304: 2124306
73TSC2NM_000548.3(TSC2): c.1444-2A> Gsingle nucleotide variantPathogenicrs45517174GRCh37Chr 16, 2114271: 2114271
74TSC2NM_000548.3(TSC2): c.1831C> T (p.Arg611Trp)single nucleotide variantPathogenicrs45469298GRCh37Chr 16, 2120571: 2120571
75TSC2NM_000548.3(TSC2): c.1599+1G> Asingle nucleotide variantPathogenicrs45517182GRCh37Chr 16, 2114429: 2114429
76TSC2NM_000548.3(TSC2): c.1229T> G (p.Leu410Arg)single nucleotide variantLikely pathogenicrs137854298GRCh37Chr 16, 2111981: 2111981
77TSC2NM_000548.3(TSC2): c.2071delC (p.Arg691Alafs)deletionPathogenicrs137854071GRCh37Chr 16, 2121909: 2121909
78TSC2NM_000548.3(TSC2): c.2410T> C (p.Cys804Arg)single nucleotide variantLikely pathogenic, Pathogenicrs137853995GRCh37Chr 16, 2124255: 2124255
79TSC2NM_000548.3(TSC2): c.2108G> A (p.Trp703Ter)single nucleotide variantPathogenicrs45517213GRCh37Chr 16, 2122252: 2122252
80TSC2NM_000548.3(TSC2): c.3598C> T (p.Arg1200Trp)single nucleotide variantPathogenicrs45438205GRCh37Chr 16, 2130366: 2130366
81TSC2NM_000548.3(TSC2): c.2546-2A> Gsingle nucleotide variantPathogenicrs45517246GRCh37Chr 16, 2125798: 2125798
82TSC2NM_000548.3(TSC2): c.2639+1G> Csingle nucleotide variantPathogenicrs45517252GRCh37Chr 16, 2125894: 2125894
83TSC2NM_000548.3(TSC2): c.4912_4914delAAG (p.Lys1638del)deletionPathogenicrs137854261GRCh37Chr 16, 2136795: 2136797
84TSC2NM_000548.3(TSC2): c.848+1G> Asingle nucleotide variantPathogenicrs45466296GRCh37Chr 16, 2107180: 2107180
85TSC2NM_000548.3(TSC2): c.5138G> A (p.Arg1713His)single nucleotide variantPathogenicrs45517395GRCh37Chr 16, 2138118: 2138118
86TSC2NM_000548.3(TSC2): c.5138G> C (p.Arg1713Pro)single nucleotide variantLikely pathogenicrs45517395GRCh37Chr 16, 2138118: 2138118
87TSC2NM_000548.3(TSC2): c.5170C> T (p.Gln1724Ter)single nucleotide variantPathogenicrs45472701GRCh37Chr 16, 2138237: 2138237
88TSC2NM_000548.3(TSC2): c.5228G> A (p.Arg1743Gln)single nucleotide variantPathogenicrs45507199GRCh37Chr 16, 2138295: 2138295
89TSC2NM_000548.3(TSC2): c.4934_4935delTT (p.Phe1645Cysfs)deletionPathogenicrs137854249GRCh37Chr 16, 2136817: 2136818
90TSC2NM_000548.3(TSC2): c.4375C> T (p.Arg1459Ter)single nucleotide variantPathogenicrs45517340GRCh37Chr 16, 2134598: 2134598
91TSC2NM_000548.3(TSC2): c.569dupA (p.Tyr190Terfs)duplicationPathogenicrs137854359GRCh37Chr 16, 2105490: 2105490
92TSC2NM_000548.3(TSC2): c.3106T> C (p.Ser1036Pro)single nucleotide variantPathogenicrs45517281GRCh37Chr 16, 2129172: 2129172
93TSC2NM_000548.3(TSC2): c.4180_4181delCT (p.Leu1394Alafs)deletionPathogenicrs137854363GRCh37Chr 16, 2134403: 2134404
94TSC2NM_000548.3(TSC2): c.3397+5G> Asingle nucleotide variantPathogenicrs45501492GRCh37Chr 16, 2129675: 2129675
95TSC2NM_000548.3(TSC2): c.3401delG (p.Gly1134Alafs)deletionPathogenicrs137854314GRCh37Chr 16, 2130169: 2130169
96TSC2NM_000548.3(TSC2): c.4762C> T (p.Gln1588Ter)single nucleotide variantPathogenicrs45479192GRCh37Chr 16, 2136293: 2136293
97TSC2NM_000548.3(TSC2): c.2251C> T (p.Arg751Ter)single nucleotide variantPathogenicrs45517222GRCh37Chr 16, 2122880: 2122880
98TSC2NM_000548.3(TSC2): c.3611G> A (p.Gly1204Glu)single nucleotide variantLikely pathogenicrs45462194GRCh37Chr 16, 2131596: 2131596
99TSC2NM_000548.3(TSC2): c.1255C> T (p.Pro419Ser)single nucleotide variantPathogenicrs45517159GRCh37Chr 16, 2112007: 2112007
100TSC1NM_000368.4(TSC1): c.1888_1891delAAAG (p.Lys630Glnfs)deletionPathogenicrs118203595GRCh37Chr 9, 135781074: 135781077
101TSC1NM_000368.4(TSC1): c.749T> A (p.Leu250Ter)single nucleotide variantPathogenicrs118203447GRCh37Chr 9, 135787833: 135787833
102TSC1NM_000368.4(TSC1): c.1760A> G (p.Lys587Arg)single nucleotide variantPathogenicrs118203576GRCh37Chr 9, 135781205: 135781205
103TSC1NM_000368.4(TSC1): c.1904_1905delCA (p.Thr635Argfs)deletionPathogenicrs118203598GRCh37Chr 9, 135781060: 135781061
104TSC1NM_000368.4(TSC1): c.1671_1693del23 (p.Ser561Argfs)deletionPathogenicrs118203557GRCh37Chr 9, 135781272: 135781294
105TSC1NM_000368.4(TSC1): c.671T> G (p.Met224Arg)single nucleotide variantPathogenicrs118203426GRCh37Chr 9, 135796816: 135796816
106TSC1NM_000368.4(TSC1): c.539T> C (p.Leu180Pro)single nucleotide variantPathogenicrs118203396GRCh37Chr 9, 135797330: 135797330
107TSC1NM_000368.4(TSC1): c.2041+1G> Asingle nucleotide variantPathogenicrs397514842GRCh37Chr 9, 135779797: 135779797
108TSC1NM_000368.4(TSC1): c.866C> G (p.Ser289Ter)single nucleotide variantPathogenicrs397514867GRCh37Chr 9, 135787716: 135787716
109TSC1NM_000368.4(TSC1): c.2698C> T (p.Gln900Ter)single nucleotide variantPathogenicrs397514871GRCh37Chr 9, 135772925: 135772925
110TSC1NM_000368.4(TSC1): c.2672delA (p.Asn891Thrfs)deletionPathogenicrs397514875GRCh37Chr 9, 135772951: 135772951
111TSC2NM_000548.3(TSC2): c.1447G> T (p.Glu483Ter)single nucleotide variantPathogenicrs397515297GRCh37Chr 16, 2114276: 2114276
112TSC2NM_000548.3(TSC2): c.4147_4163dup17 (p.Pro1389Alafs)duplicationPathogenicrs397515009GRCh37Chr 16, 2134370: 2134386
113TSC2NM_000548.3(TSC2): c.3236C> A (p.Ser1079Ter)single nucleotide variantPathogenicrs397515087GRCh37Chr 16, 2129381: 2129381
114TSC2NM_000548.3(TSC2): c.1959_1960delAG (p.Gly654Leufs)deletionPathogenicrs397515226GRCh37Chr 16, 2121797: 2121798

Expression for genes affiliated with Tuberous Sclerosis

About this section
Search GEO for disease gene expression data for Tuberous Sclerosis.

Pathways for genes affiliated with Tuberous Sclerosis

About this section

Pathways related to Tuberous Sclerosis according to GeneCards Suite gene sharing:

(show top 50)    (show all 60)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
110.0MTOR, TSC1, TSC2
29.7EIF4EBP1, MTOR, RAP1A
39.6AKT1, AKT3, RAP1A
4
Show member pathways
9.5AKT1, AKT3, MTOR, TSC2
59.5AKT1, CCL26, MTOR, RPS6KB1
69.5AKT1, EIF4EBP1, RPS6KB1
7
Show member pathways
9.4AKT1, AKT3, MTOR, RAP1A
8
Show member pathways
9.4AKT1, EIF4EBP1, MTOR, VIM
9
Show member pathways
9.4AKT1, AKT3, MTOR, RHEB
109.4DBH, DCX, GFAP, S100B, SYP
119.4AKT1, AKT3, MTOR, RPS6KB1
12
TGF-beta Signaling Pathway (sino)
Show member pathways
9.4AKT1, AKT3, MTOR, RPS6KB1
13
Show member pathways
9.3AKT1, MTOR, RAP1A, RPS6
14
Show member pathways
9.3AKT1, EIF4EBP1, MTOR, RPS6KB1
15
Show member pathways
9.3AKT1, MTOR, RPS6, RPS6KB1
169.3AKT1, AKT3, RHEB, TSC1, TSC2
179.2AKT1, AKT3, MTOR, RHEB, TSC2
189.2AKT1, EIF4EBP1, MTOR, RPS6
19
Show member pathways
9.2AKT1, AKT3, MTOR, NF1, TSC1, TSC2
209.2EIF4EBP1, MTOR, RPS6, RPS6KB1
21
Show member pathways
9.1EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC2
22
Show member pathways
9.1AKT1, AKT3, MTOR, RHEB, TSC1, TSC2
239.0AKT1, MTOR, RAP1A, RPS6, RPS6KB1
24
Show member pathways
9.0AKT1, AKT3, EIF4EBP1, MTOR, RPS6KB1
259.0AKT1, AKT3, MTOR, RPS6, RPS6KB1
268.9AKT1, MTOR, NF1, RAP1A, RHEB, TSC1
27
Show member pathways
8.9AKT1, AKT3, MTOR, RHEB, RPS6KB1, TSC2
288.9EIF4EBP1, MTOR, RPS6, RPS6KB1, TSC1, TSC2
298.8AKT1, AKT3, MTOR, NF1, RPS6KB1, TSC1
30
Show member pathways
8.8AKT1, AKT3, EIF4EBP1, MTOR, RPS6KB1, TSC2
31
Show member pathways
8.8AKT1, EIF4EBP1, MTOR, RAP1A, RHEB, TSC1
328.7AKT1, EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC1
338.7AKT1, EIF4EBP1, MTOR, RHEB, RPS6KB1, TSC1
34
Show member pathways
8.7AKT1, AKT3, MTOR, RAP1A, RPS6, RPS6KB1
35
Show member pathways
8.7AKT1, AKT3, EIF4EBP1, MTOR, RPS6KB1, TSC1
36
Show member pathways
8.6AKT1, AKT3, MTOR, RAP1A, RHEB, RPS6KB1
378.6AKT1, AKT3, EIF4EBP1, MTOR, RPS6, RPS6KB1
38
Show member pathways
8.6AKT1, AKT3, EIF4EBP1, MTOR, RPS6, RPS6KB1
39
Show member pathways
8.5AKT1, AKT3, EIF4EBP1, MTOR, RHEB, RPS6KB1
408.5AKT1, EIF4EBP1, MTOR, RAP1A, RPS6, RPS6KB1
418.4AKT1, EIF4EBP1, MTOR, RHEB, RPS6, RPS6KB1
428.4AKT1, AKT3, EIF4EBP1, MTOR, RHEB, RPS6KB1
43
Show member pathways
8.4AKT1, AKT3, EIF4EBP1, MTOR, RHEB, RPS6KB1
448.4AKT1, AKT3, EIF4EBP1, MTOR, RHEB, RPS6KB1
45
Show member pathways
8.3AKT1, EIF4EBP1, MTOR, RHEB, RPS6, RPS6KB1
46
Show member pathways
8.3AKT1, EIF4EBP1, MTOR, RHEB, RPS6, RPS6KB1
47
Show member pathways
8.0AKT1, AKT3, CCL26, GFAP, MTOR, NF1
48
Show member pathways
8.0AKT1, AKT3, EIF4EBP1, MTOR, RHEB, RPS6
49
Show member pathways
8.0AKT1, AKT3, EIF4EBP1, MTOR, RHEB, RPS6
508.0AKT1, AKT3, EIF4EBP1, MTOR, RHEB, RPS6

GO Terms for genes affiliated with Tuberous Sclerosis

About this section

Cellular components related to Tuberous Sclerosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1TSC1-TSC2 complexGO:003359610.9TSC1, TSC2
2neuron projectionGO:00430059.6DCX, RAP1A, RPS6KB1, SYP, VIM
3membraneGO:00160207.9DBH, GFAP, MTOR, NF1, PKD1, RAP1A
4cytosolGO:00058296.7AKT1, DCX, EIF4EBP1, GFAP, MTOR, NF1
5cytoplasmGO:00057376.3AKT1, AKT3, DBH, DCX, EIF4EBP1, GFAP

Biological processes related to Tuberous Sclerosis according to GeneCards Suite gene sharing:

(show all 30)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycleGO:003165910.7AKT1, PKD1
2regulation of glycogen biosynthetic processGO:000597910.7AKT1, MTOR
3insulin-like growth factor receptor signaling pathwayGO:004800910.7AKT1, TSC2
4response to fluid shear stressGO:003440510.7AKT1, PKD1
5intermediate filament-based processGO:004510310.7GFAP, VIM
6intermediate filament organizationGO:004510910.7GFAP, VIM
7Bergmann glial cell differentiationGO:006002010.7GFAP, VIM
8astrocyte developmentGO:001400210.6GFAP, VIM
9positive regulation of lipid biosynthetic processGO:004688910.5AKT1, MTOR
10negative regulation of cell sizeGO:004579210.5AKT1, MTOR, TSC1
11positive regulation of oligodendrocyte differentiationGO:004871410.5MTOR, RHEB
12regulation of cell-matrix adhesionGO:000195210.5NF1, TSC1
13negative regulation of protein kinase activityGO:000646910.4AKT1, NF1, TSC2
14negative regulation of insulin receptor signaling pathwayGO:004662710.4RPS6KB1, TSC1, TSC2
15activation-induced cell death of T cellsGO:000692410.4AKT1, RPS6
16cell projection organizationGO:003003010.3AKT1, MTOR, TSC1
17response to insulinGO:003286810.3MTOR, RPS6KB1, TSC1
18protein kinase B signalingGO:004349110.2AKT1, RPS6KB1, TSC2
19peptidyl-serine phosphorylationGO:001810510.1AKT1, DCX, MTOR, PKD1
20germ cell developmentGO:000728110.1AKT1, MTOR, RPS6KB1
21positive regulation of endothelial cell proliferationGO:000193810.0AKT1, CCL26, MTOR, NF1
22phosphatidylinositol-mediated signalingGO:004801510.0AKT1, MTOR, RPS6KB1, TSC2
23cellular response to insulin stimulusGO:00328699.9AKT1, RPS6KB1, TSC2
24transcription initiation from RNA polymerase II promoterGO:00063679.9AKT1, MTOR, RHEB, TSC1, TSC2
25cell cycle arrestGO:00070509.9MTOR, PKD1, RHEB, TSC1, TSC2
26TOR signalingGO:00319299.7EIF4EBP1, MTOR, RPS6, RPS6KB1
27neurotrophin TRK receptor signaling pathwayGO:00480119.6AKT1, MTOR, NF1, RAP1A, TSC2
28gene expressionGO:00104678.7AKT1, EIF4EBP1, MTOR, RHEB, RPS6, TSC1
29signal transductionGO:00071658.4AKT1, AKT3, CCL26, MTOR, NF1, RAP1A
30insulin receptor signaling pathwayGO:00082868.3AKT1, EIF4EBP1, MTOR, NF1, RHEB, RPS6

Molecular functions related to Tuberous Sclerosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein phosphatase 2A bindingGO:00517219.9AKT1, EIF4EBP1, RPS6KB1
2protein kinase bindingGO:00199019.1AKT1, DCX, PKD1, RHEB, RPS6

Sources for Tuberous Sclerosis

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet